Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f

Sköld, K.; H-Stenstam, B.; Diaz, Aidnag; Giusti, Valerio; Pellettieri, Luigi; Hopewell, J. W.

doi:10.1111/j.1600-0404.2009.01267.x

Cited by 50 publications

(29 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Kaplan-Meier plots comparing the survival for all patients from the two arms of the randomised trial by Stupp et al [4] with the Studsvik BNCT study [8,9] are shown in Figure 1a,b. A similar analysis for RPA Class V patients alone [3] is given in Figure 1c,d.…”

Section: Resultsmentioning

confidence: 99%

“…The patient characteristics and medical interventions in the two arms of the trial as published by Mirimanoff et al [3] and as published in the BNCT study [9] are given in Table 1. The median age of the patients in the BNCT study was slightly lower, and the fraction of patients with initial surgery was slightly higher, than indicated by Mirimanoff et al [3].…”

Section: Methodsmentioning

confidence: 99%

“…The updated European Organisation for Research and Treatment of Cancer (EORTC) data files from the original study by Stupp et al [4], reported previously in publications by Mirimanoff et al [3], Gorlia et al [5] and Hegi et al [6], and the updated data from the Studsvik BNCT study [9] were used in the present analysis. The clinical observations were compared using two approaches, namely univariate analyses based on the results for patient survival from Kaplan-Meier curves for BNCT vs either RT or RT/TMZ and the Cox proportional hazard model, which was used to adjust for factors such as the extent of initial surgery, age, World Health Organization (WHO) performance status and RPA class at the time of diagnosis.…”

Section: Methodsmentioning

confidence: 99%

“…A detailed comparison of two BNCT studies, in which the baseline characteristics of the patient populations where available was reported recently [9], namely the Phase II study at Studsvik using a 6-h infusion of L-boronophenylalanine (L-BPA) as the fructose preparation BPA-f, and the Phase I/II study at Brookhaven National Laboratory (BNL) using a 2-h infusion of BPA-f. A significant survival benefit of the prolonged infusion was observed. The Studsvik study represents the stateof-the-art in the application of BNCT to newly diagnosed GBM and is therefore used in the present assessment of the efficacy of BNCT relative to present standard treatment.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential

Sköld¹,

Gorlia²,

Pellettieri³

et al. 2010

BJR

View full text Add to dashboard Cite

ABSTRACT. The purpose of this study was to assess the potential of boron neutron capture therapy (BNCT), with a 6-h infusion of the boron carrier L-boronophenylalanine as a fructose preparation (BPA-f), as first-line radiotherapy for newly diagnosed glioblastoma multiforme (GBM). Patient survival data from a Phase II study using BNCT were compared with retrospective data from the two arms of a Phase III study using conventional radiotherapy (RT) in the reference arm and using RT plus concomitant and adjuvant medication with temozolomide (TMZ) in the experimental arm, and were also compared with small subgroups of these patients for whom the methylation status of the MGMT (O 6 -methylguanine-DNA methyltransferase) DNA repair gene was known. Differences in the baseline characteristics, salvage therapy after recurrence and levels of severe adverse events were also considered. The results indicate that BNCT offers a treatment that is at least as effective as conventional RT alone. For patients with an unmethylated MGMT DNA repair gene, a possible clinical advantage of BNCT over RT/ TMZ was suggested. BNCT is a single-day treatment, which is of convenience to patients, with mild side effects, which would offer an initial 6 weeks of good-quality life during the time when patients would otherwise be undergoing daily treatments with RT and TMZ. It is suggested that the use of BNCT with a 6-h infusion of BPA-f should be explored in a stratified randomised Phase II trial in which patients with the unmethylated MGMT DNA repair gene are offered BNCT in the experimental arm and RT plus TMZ in the reference arm. Boron neutron capture therapy (BNCT) is an experimental radiotherapy that, to date, has mostly been applied to treating patients with newly diagnosed glioblastoma multiforme (GBM). Several hundred GBM patients have been treated in Phase I and Phase II studies in Europe, the USA and Japan, and survival times similar to those obtained with standard radiotherapy (RT) have been reported from several of these studies [1]. No randomised trial in which BNCT is compared with standard therapies has yet been undertaken.Proper assessment of the results from these Phase II trials has been hampered by the lack of information on baseline characteristics of the patient populations, both in reports of the BNCT studies and in reports on other therapies, notably standard fractionated photon therapy (RT), to which the results from BNCT should ultimately be compared. The recursive partitioning analysis (RPA) of prognostic factors by Curran et al [2] established a method to characterise patient status prior to treatment, useful both for the planning of clinical studies and for the assessment of the significance of the results from clinical studies. The reliability and usefulness of the RPA method has been verified by Mirimanoff et al [3] by applying it to data obtained from a randomised Phase III study [4], in which RT with concomitant and adjuvant temozolomide (RT/TMZ) was offered to 287 patients with newly diagnosed GBM in the experimen...

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential

Sköld¹,

Gorlia²,

Pellettieri³

et al. 2010

BJR

View full text Add to dashboard Cite

show abstract

“…In that trial the MST was 10.4-13.2 months for newly diagnosed GBM patients. In a Swedish clinical trial 29 newly diagnosed GBM patients received an infusion of 900 mg/kg BPA in the course of 6 hours (22)(23)(24)(25). The MST was 17.7 months compared to 15.5 months in patients who received standard therapy comprised of surgery followed by RT and TMZ.…”

Section: Discussionmentioning

confidence: 99%

Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: Comparison of clinical results obtained with BNCT and conventional treatment

et al. 2014

View full text Add to dashboard Cite

: The purpose of this study was to evaluate the clinical outcome of boron neutron capture therapy (BNCT) and conventional treatment in patients with newly diagnosed glioblastoma. Since 1998 we treated 23 newly-diagosed GBM patients with BNCT without any additional chemotherapy. Their median survival time was 19.5 months ; the 2-, 3-, and 5-year survival rates were 31.8% %, 22.7% %, and 9.1% %, respectively. The clinical results of BNCT in patients with GBM are similar to those of recent conventional treatments based on radiotherapy with concomitant and adjuvant temozolomide.

show abstract

Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT

Barth,

Gupta,

Kawabata

2024

Cancer Communications

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a cancer treatment modality based on the nuclear capture and fission reactions that occur when boron‐10, a stable isotope, is irradiated with neutrons of the appropriate energy to produce boron‐11 in an unstable form, which undergoes instantaneous nuclear fission to produce high‐energy, tumoricidal alpha particles. The primary purpose of this review is to provide an update on the first drug used clinically, sodium borocaptate (BSH), by the Japanese neurosurgeon Hiroshi Hatanaka to treat patients with brain tumors and the second drug, boronophenylalanine (BPA), which first was used clinically by the Japanese dermatologist Yutaka Mishima to treat patients with cutaneous melanomas. Subsequently, BPA has become the primary drug used as a boron delivery agent to treat patients with several types of cancers, specifically brain tumors and recurrent tumors of the head and neck region. The focus of this review will be on the initial studies that were carried out to define the pharmacokinetics and pharmacodynamics of BSH and BPA and their biodistribution in tumor and normal tissues following administration to patients with high‐grade gliomas and their subsequent clinical use to treat patients with high‐grade gliomas. First, we will summarize the studies that were carried out in Japan with BSH and subsequently at our own institution, The Ohio State University, and those of several other groups. Second, we will describe studies carried out in Japan with BPA and then in the United States that have led to its use as the primary drug that is being used clinically for BNCT. Third, although there have been intense efforts to develop new and better boron delivery agents for BNCT, none of these have yet been evaluated clinically. The present report will provide a guide to the future clinical evaluation of new boron delivery agents prior to their clinical use for BNCT.

show abstract

Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-f

Cited by 50 publications

References 20 publications

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential

Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential

Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma: Comparison of clinical results obtained with BNCT and conventional treatment

Evaluation of sodium borocaptate (BSH) and boronophenylalanine (BPA) as boron delivery agents for neutron capture therapy (NCT) of cancer: an update and a guide for the future clinical evaluation of new boron delivery agents for NCT

Contact Info

Product

Resources

About